Assertio Holdings (ASRT) Company Report

Assertio Holdings, Inc. (ASRT) filed a Certificate of Amendment to its certificate of incorporation on December 19, 2025, to implement a reverse stock split.
The reverse stock split will be at a ratio of 1:15 and was approved by stockholders on May 7, 2025.
The Reverse Split will become effective at 12:01 a.m. Eastern Time on December 26, 2025, with split-adjusted trading expected to commence on the same day.
No fractional shares will be issued; instead, stockholders will receive a cash payment based on the closing price of the Common Stock on the Nasdaq Stock Market on December 24, 2025.
Proportionate adjustments will be made to the conversion rate of the company's 6.5% Convertible Senior Notes due 2027 and to its equity incentive compensation plans.

Dec 22, 2025, 9:37 PM

8-K

Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split

ASRT

Delisting/Listing Issues

Assertio Holdings, Inc. announced a 1-for-15 reverse stock split.
The reverse split will become effective, and the company's common stock will begin trading on a split-adjusted basis, on December 26, 2025.
The primary reason for the reverse stock split is to maintain the company's Nasdaq listing.
Every fifteen shares of common stock will automatically convert into one share, with proportionate adjustments to the conversion rate of 6.5% Convertible Senior Notes due 2027 and equity incentive compensation plans.

Dec 22, 2025, 9:30 PM

Press Release

Assertio Holdings Reports Q3 2025 Results, Rosedown Sales Pull Forward, and Narrows Full Year Guidance

ASRT

Earnings

Management Change

Guidance Update

Assertio Holdings reported total product sales of $49.5 million for Q3 2025, an increase from $28.7 million in the prior year, primarily driven by a Rosedown pull forward.
Rosedown net product sales were $38.6 million in Q3 2025, up from $15 million in the prior year quarter, due to the pull forward of two quarters of sales through the wholesale distribution channel. This action was taken to ensure uninterrupted patient supply during a transition, and no material Rosedown sales are anticipated in Q4 2025 and Q1 2026, with regular sales expected to resume in Q2 2026.
The company achieved adjusted EBITDA of $20.9 million for Q3 2025, significantly up from $4.4 million in the prior year quarter, and GAAP net income of $11.4 million compared to a loss of $3 million in the prior year.
Assertio Holdings narrowed its full year 2025 guidance, anticipating product sales between $110 million and $112 million and adjusted EBITDA between $14 million and $16 million, reflecting the impact of the Rosedown pull forward and other factors.
Mark Wisenaar assumed the role of CEO, and Paul Schwichtenberg was promoted to President and Chief Operating Officer.

Nov 10, 2025, 9:30 PM

Transcript

Assertio Holdings, Inc. Reports Q3 2025 Financial Results and Updates FY2025 Guidance

ASRT

Earnings

Guidance Update

Management Change

Assertio Holdings, Inc. reported Net Product Sales of $49.5 million and Adjusted EBITDA of $20.9 million for the third quarter of 2025, significantly increasing from $28.7 million and $4.4 million, respectively, in the prior-year quarter.
Rolvedon net product sales were a key driver, reaching $38.6 million in Q3 2025, up from $15.0 million in the prior-year quarter, reflecting normal demand and large distributor purchases.
The company narrowed its FY2025 Net Product Sales guidance range to $110 million to $112 million and its Adjusted EBITDA guidance range to $14 million to $16 million.
Paul Schwichtenberg was promoted to President and Chief Operating Officer.

Nov 10, 2025, 9:13 PM

8-K

Assertio Reports Q3 2025 Financial Results and Updates Guidance

ASRT

Earnings

Guidance Update

Management Change

Assertio reported Net Product Sales of $49.5 million and Adjusted EBITDA of $20.9 million for the third quarter ended September 30, 2025.
The company narrowed its FY2025 Net Product Sales guidance to a range of $110.0 million to $112.0 million and Adjusted EBITDA guidance to $14.0 million to $16.0 million.
Rolvedon net product sales significantly increased to $38.6 million in Q3 2025, up from $15.0 million in the prior-year quarter, partly due to large purchases by national distributors.
Paul Schwichtenberg was promoted to the newly created role of President and Chief Operating Officer.
Cash, cash equivalents, and short-term investments totaled $93.4 million as of September 30, 2025.

Nov 10, 2025, 9:13 PM

Press Release

Aquestive Therapeutics Reports Q3 2025 Financial Results and Provides Business Update

ASRT

Earnings

Guidance Update

Product Launch

Aquestive Therapeutics reported total revenues of $12.8 million for the third quarter ended September 30, 2025, and a net loss of $15.4 million, or $0.14 per basic and diluted share.
The company's New Drug Application (NDA) for Anaphylm is progressing towards a January 31, 2026 PDUFA goal date, with a potential U.S. launch in the first quarter of 2026 if approved by the FDA.
For the full-year 2025, Aquestive Therapeutics anticipates total revenue between $44 million and $50 million and a Non-GAAP adjusted EBITDA loss between $47 million and $51 million.
As of September 30, 2025, the company held $129.1 million in cash and cash equivalents.

Nov 5, 2025, 9:01 PM

Press Release

Assertio Holdings, Inc. Announces CEO Transition and New Executive Compensation

ASRT

CEO Change

Management Change

Executive Compensation

Brendan O'Grady separated from his role as Chief Executive Officer and director of Assertio Holdings, Inc. effective October 27, 2025.
Mark Reisenauer, a current board member, was appointed as the new Chief Executive Officer, effective immediately upon Mr. O'Grady's separation.
Mr. Reisenauer's compensation package includes an annual base salary of $800,000, an annual target cash bonus opportunity of 85% of his base salary, a stock option award for 1,000,000 shares, and 500,000 restricted stock units, with equity awards vesting over three years.
Assertio plans to release its third-quarter 2025 financial results on November 10, 2025, and expects to update guidance within the current range at that time.

Oct 30, 2025, 8:46 PM

8-K

Assertio Holdings' Subsidiary Amends ROLVEDON Supply Agreement

ASRT

Assertio Holdings, Inc.'s subsidiary, Spectrum Pharmaceuticals, Inc., entered into an amendment and restatement of its supply agreement with Hanmi Pharmaceutical Co. Ltd. for ROLVEDON drug substance on October 7, 2025.
The amendment establishes long-term pricing for ROLVEDON, including a mid-single digit percentage reduction to the price Spectrum previously agreed to pay.
The new price is fixed throughout the remaining term of Spectrum's license agreement, subject to potential price increases from January 1, 2028, if the supplier's costs exceed a set threshold, and potential reductions if global market volume for ROLVEDON exceeds a specified threshold.
Spectrum is required to provide an annual forecasted purchase plan, with at least fifty percent of any included orders designated as binding, though there are no minimum purchase requirements.